CN

Contact Us

010-69739712

WeChat

美高梅4858网站(中国)控股公司

The company takes the immune cell therapy of hematological tumors and solid tumors as the main research and development direction, and establishes targeted cell therapy with CAR-T and CAR-NK as the main technology platform.